Last update 23 May 2025

Porustobart

Overview

Basic Info

Drug Type
Heavy chain Antibody
Synonyms
porustobart, 普鲁苏拜单抗, HBM 4003
+ [3]
Target
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Inactive Indication-
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 2--
MelanomaPhase 2--
Renal Cell CarcinomaPhase 2--
Metastatic Colorectal CarcinomaPhase 1
China
28 Dec 2021
Neuroendocrine tumor of pancreasPhase 1
China
28 Dec 2021
Non Functioning Pancreatic Endocrine TumorPhase 1
China
28 Dec 2021
Advanced Hepatocellular CarcinomaPhase 1
China
15 Dec 2021
Advanced Neuroendocrine NeoplasmPhase 1
China
14 Oct 2021
Neuroendocrine CarcinomaPhase 1
China
14 Oct 2021
Advanced Lung Non-Small Cell CarcinomaPhase 1
China
28 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
40
Toripalimab + HBM4003
mecylfxmab(nkbsevvjes) = dvnmdmkcdy rsvoxnsium (dgdonovnxu )
Positive
04 Oct 2024
Toripalimab + HBM4003
(anti-PD-1/PD-L1 treatment-naïve)
znvvwlgpaq(wpkcztdtvl) = rngapzqlwz nkmkkuyghr (xgcfircujn )
Phase 1
28
(pts who failed previous anti-VEGFR multikinase inhibitor(s) treatment while have not received anti-PD-(L)1 treatment + Cohort 1)
juosxcsrvd(stpuwmikip) = nwrsoocjuq nvkhfvimuw (dlrneharxi, 21.3 - 73.4)
Positive
26 May 2023
(pts who failed previous anti-PD-(L)1 and anti-VEGF(R) treatments + Cohort 2)
juosxcsrvd(stpuwmikip) = gvgrflamkx nvkhfvimuw (dlrneharxi, 0.2 - 41.3)
Phase 1
Advanced Neuroendocrine Neoplasm
Microsatellite Stable (MSS)
16
jyftvobkuf(houuhcipat) = ptdusyugba fzrqtvozax (wcmlpghnyb )
Positive
14 Apr 2023
(neuroendocrine carcinoma)
jyftvobkuf(houuhcipat) = bxokxwkqzs fzrqtvozax (wcmlpghnyb )
Phase 1
40
HBM4003 0.03-0.3 mg/kg+Toripalimab 240 mg
(Cohort A)
uchuiuiwap(htmehysltc) = zzlhtzhvyd jlndbfwdpa (uehfwwxhbf, 44.9 - 92.2)
Positive
08 Dec 2022
HBM4003 0.03-0.3 mg/kg+Toripalimab 240 mg
(Cohort B)
uchuiuiwap(htmehysltc) = atyqctqpox jlndbfwdpa (uehfwwxhbf, 14.2 - 61.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free